Form 10-Q NEUROCRINE BIOSCIENCES For: Mar 31
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/5/2026
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Goldman's Garrett sees investors dialing back tech exposure into H2
- AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
- Oil gains on short-covering buys ahead of US holiday
- Rivian stock jumps 5% on raised delivery outlook
Stifel on Neurocrine Bio. (NBIX): 'Really Nice Ingrezza Quarter, Guidance Starting to Look Potentially Conservative'
May 4, 2022 10:25 AM EDTStifel analyst Paul Matteis reiterated a Buy rating and $136.00 price target on Neurocrine Bio. (NASDAQ: NBIX).
The analyst comments "We are reiterating our Buy rating on NBIX on a strong quarter for Ingrezza ($303MM) which beat our estimate and consensus by ~$23MM and... More
Raymond James on Neurocrine Bio. (NBIX): 'Solid Beat for Ingrezza; Well Positioned Moving Forward'
May 4, 2022 10:24 AM EDTRaymond James analyst Danielle Brill reiterated an Outperform rating on Neurocrine Bio. (NASDAQ: NBIX).
The analyst comments "Ingrezza 1Q revenues solidly beat expectations, and FY22 guidance was rea"irmed. Lighter seasonal payer headwinds and enhanced compliance helped contribute to the strong Ingrezza revenue... More
